News Quantified

RIGL – rigel pharmaceuticals, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? [Yahoo! Finance]

Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at Citigroup Inc..

Rigel Provides Business Update and 2026 Outlook [Yahoo! Finance]

Rigel Provides Business Update and 2026 Outlook

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

33.4%

BEAT

23.0%

BEAT

1.2%

BEAT

-8.1%

BEAT

Form 8-K RIGEL PHARMACEUTICALS For: Jan 12

Form 4 RIGEL PHARMACEUTICALS For: Dec 22 Filed by: Schorno Dean L

Form 8-K RIGEL PHARMACEUTICALS For: Dec 07

Form SCHEDULE 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Form 8-K RIGEL PHARMACEUTICALS For: Nov 04

Top News Gainers

1/13 Form 8-K RIGEL PHARMACEUTICALS For: Jan 13 20.0%

10/23 Here's Why Rigel Pharmaceuticals Stock Jumped as Much as 10.7% Today [The Motley Fool] 17.1%

4/27 Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update 9.0%

2/27 Rigel Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] 6.5%

6/28 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 6.5%

3/4 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.4%

5/23 Form 4 RIGEL PHARMACEUTICALS For: May 22 Filed by: Schorno Dean L 5.9%

5/21 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.9%

9/23 Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia 5.1%

8/6 Q2/2019 6/30/2019 EPS -0.120 ZacksConsensus -0.140 ActVsEst 0.020 - Beat 4.6%

Top News Decliners

4/1 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock. -11.9%

11/6 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -9.9%

5/7 Form 8-K RIGEL PHARMACEUTICALS For: May 07 -7.4%

12/17 Rigel Announces Chief Commercial Officer Transition -6.4%

8/10 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.50 price target on the stock. -6.4%

4/30 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.8%

10/29 Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results -5.7%

5/1 Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders -5.5%

10/18 Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha] -4.9%

9/26 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock. -4.8%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day